Total Payments
$137,567
2024 Payments
$7,450
Companies
11
Transactions
90
Medicare Patients
64
Medicare Billing
$6,549
Payment Breakdown by Category
Consulting$96,833 (70.4%)
Travel$27,158 (19.7%)
Research$6,420 (4.7%)
Other$4,700 (3.4%)
Education$1,816 (1.3%)
Food & Beverage$639.51 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $96,833 | 27 | 70.4% |
| Travel and Lodging | $27,158 | 33 | 19.7% |
| Unspecified | $6,420 | 11 | 4.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,700 | 2 | 3.4% |
| Education | $1,816 | 2 | 1.3% |
| Food and Beverage | $639.51 | 15 | 0.5% |
Payments by Type
General
$131,147
79 transactions
Research
$6,420
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UCB SA | $80,540 | 39 | $0 (2024) |
| UCB, Inc. | $19,524 | 20 | $0 (2023) |
| UCB GmBH | $10,056 | 2 | $0 (2017) |
| Regeneron Pharmaceuticals, Inc. | $6,358 | 8 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $5,938 | 13 | $0 (2018) |
| Lilly USA, LLC | $5,600 | 1 | $0 (2021) |
| PFIZER INC. | $4,700 | 2 | $0 (2017) |
| GlaxoSmithKline, LLC. | $3,680 | 1 | $0 (2020) |
| Amgen Inc. | $591.80 | 2 | $0 (2022) |
| UCB Biosciences Inc. | $550.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,450 | 3 | UCB SA ($7,450) |
| 2023 | $21,213 | 9 | UCB SA ($20,273) |
| 2022 | $11,830 | 4 | UCB SA ($11,250) |
| 2021 | $22,985 | 14 | UCB SA ($10,080) |
| 2020 | $6,440 | 2 | GlaxoSmithKline, LLC. ($3,680) |
| 2019 | $2,907 | 2 | UCB, Inc. ($2,880) |
| 2018 | $26,780 | 25 | UCB SA ($15,135) |
| 2017 | $37,962 | 31 | UCB SA ($16,352) |
All Payment Transactions
90 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/29/2024 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $1,380.00 | General |
| 05/02/2024 | UCB SA | Cimzia (Drug) | Consulting Fee | Cash or cash equivalent | $3,550.00 | General |
| Category: Immunology | ||||||
| 01/11/2024 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $2,520.00 | General |
| 09/21/2023 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| 07/20/2023 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $11,308.33 | General |
| 05/04/2023 | UCB, Inc. | — | Travel and Lodging | Cash or cash equivalent | $302.70 | General |
| 03/07/2023 | UCB, Inc. | — | Travel and Lodging | In-kind items and services | $268.88 | General |
| 03/07/2023 | UCB, Inc. | — | Travel and Lodging | In-kind items and services | $267.80 | General |
| 03/07/2023 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $49.99 | General |
| 03/07/2023 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $49.98 | General |
| 01/20/2023 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $2,875.00 | General |
| 01/13/2023 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $1,890.00 | General |
| 12/02/2022 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $5,040.00 | General |
| 10/07/2022 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $580.00 | General |
| 07/29/2022 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $4,025.00 | General |
| 01/14/2022 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $2,185.00 | General |
| 12/14/2021 | UCB, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,725.00 | General |
| 10/22/2021 | UCB, Inc. | — | — | In-kind items and services | $400.00 | Research |
| Study: Pharmacovigilance data on pregnancy outcomes in women with Crohn disease exposed to certolizumab pegol | ||||||
| 10/07/2021 | UCB, Inc. | — | — | In-kind items and services | $2,300.00 | Research |
| Study: Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol | ||||||
| 09/14/2021 | UCB, Inc. | — | — | In-kind items and services | $400.00 | Research |
| Study: Pharmacovigilance data on pregnancy outcomes in women with psoriatic disease exposed to certolizumab pegol | ||||||
| 08/26/2021 | UCB, Inc. | — | — | In-kind items and services | $400.00 | Research |
| Study: Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol | ||||||
| 08/19/2021 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| 08/19/2021 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| 06/21/2021 | UCB, Inc. | — | — | In-kind items and services | $420.00 | Research |
| Study: Pharmacovigilance data on pregnancy outcomes in women with Crohns disease exposed to certolizumab pegol | ||||||
| 06/02/2021 | UCB, Inc. | — | — | In-kind items and services | $400.00 | Research |
| Study: Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol: Pregnancy outcomes and confounders | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol | UCB, Inc. | $3,120 | 3 |
| Pregnancy Outcomes and Disease Activity in Women with Axial Spondyloarthritis: A Systematic Literature Review | UCB, Inc. | $840.00 | 2 |
| Pharmacovigilance data on pregnancy outcomes in women with psoriatic disease exposed to certolizumab pegol | UCB, Inc. | $820.00 | 2 |
| Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol: Pregnancy outcomes and confounders | UCB, Inc. | $820.00 | 2 |
| Pharmacovigilance data on pregnancy outcomes in women with Crohns disease exposed to certolizumab pegol | UCB, Inc. | $420.00 | 1 |
| Pharmacovigilance data on pregnancy outcomes in women with Crohn disease exposed to certolizumab pegol | UCB, Inc. | $400.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 12 | 15 | $5,160 | $1,148 |
| 2022 | 1 | 12 | 18 | $6,192 | $1,528 |
| 2021 | 1 | 19 | 22 | $7,568 | $1,867 |
| 2020 | 1 | 21 | 28 | $9,632 | $2,006 |
Total Patients
64
Total Services
83
Medicare Billing
$6,549
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 12 | 15 | $5,160 | $1,148 | 22.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 12 | 18 | $6,192 | $1,528 | 24.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 19 | 22 | $7,568 | $1,867 | 24.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 21 | 28 | $9,632 | $2,006 | 20.8% |
About Megan Clowse
Megan Clowse is a Rheumatology healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1063595213.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Megan Clowse has received a total of $137,567 in payments from pharmaceutical and medical device companies, with $7,450 received in 2024. These payments were reported across 90 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($96,833).
As a Medicare-enrolled provider, Clowse has provided services to 64 Medicare beneficiaries, totaling 83 services with total Medicare billing of $6,549. Data is available for 4 years (2020–2023), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Durham, NC
- Active Since 10/23/2006
- Last Updated 03/22/2013
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1063595213
Products in Payments
- Cimzia (Drug) $43,557
- KEVZARA SARILUMAB INJECTION (Biological) $6,358
- XELJANZ (Drug) $4,700
- Enbrel (Biological) $11.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Rheumatology Doctors in Durham
Ralph Snyderman, M.d, M.D
Rheumatology — Payments: $1.7M
Rheumatology $1.7M
Joseph Shanahan, Md, MD
Rheumatology — Payments: $762,544
Rheumatology $762,544
Virginia Kraus
Rheumatology — Payments: $500,154
Rheumatology $500,154
Laura Schanberg, M.d, M.D
Rheumatology — Payments: $42,792
Rheumatology $42,792
Tony Ning, Md, MD
Rheumatology — Payments: $15,743
Rheumatology $15,743
Dr. Consuelo Rabinovich, M.d, M.D
Rheumatology — Payments: $6,119
Rheumatology $6,119